Breaking News Instant updates and real-time market news.

CSCO

Cisco

$41.77

-1.81 (-4.15%)

, AMZN

Amazon.com

$1,813.00

15.99 (0.89%)

16:26
07/13/18
07/13
16:26
07/13/18
16:26

Fly Intel: Wall Street's top stories for Friday

The Dow managed to finish the week on an up note with an advance despite a tepid post-earnings performance from blue chip bank JPMorgan (JPM), which reported alongside fellow financial giants Wells Fargo (WFC) and Citi (C). The three major banks kicked off earnings season in a mixed fashion as investors brace for a significant pick up in quarterly reporting over the next few weeks. ECONOMIC EVENTS: In the U.S., the June trade price report was mixed, with a weaker than expected 0.4% import price decline and a stronger than expected 0.3% increase in export prices. The University of Michigan consumer sentiment survey was weaker than expected, falling 1.1 points to a 6-month low of 97.1 in the preliminary print for July. Baker Hughes reported that the U.S. rig count is up 2 rigs from last week to 1,054. In Asia, China's exports were strong in June, rising 11.3%, while imports fell a bit short of expectations with an increase of 14.1%. COMPANY NEWS: Shares of JPMorgan fell fractionally despite starting off this summer's earnings season by reporting better than expected earnings for the second quarter. Meanwhile, Wells Fargo slipped 1.2% after reporting downbeat results for Q2, with the company noting in presentation slides that the third party review of customer accounts is "ongoing." Citi shares also fell 2.3% after its quarterly report, though the bank's headline earnings for the quarter beat analysts' estimates. In addition, PNC Financial (PNC) reported better than expected results for the quarter and guided for third quarter net interest income to be up low-single digits... Meanwhile, AT&T (T) was in focus after the U.S. Department of Justice said it plans to appeal the approval of the merger between AT&T and Time Warner. In an interview on CNBC this morning, AT&T CEO Randall Stephenson said that the move by the DOJ "changes nothing"... Johnson & Johnson (JNJ) dipped 1.4% after a Missouri jury awarded $4.69B to 22 women who alleged that use of J&J's talcum powder products caused their ovarian cancer. The jury award includes $550M in compensatory damages and $4.14B in punitive damages against the company. J&J responded by saying it "intends to pursue all available appellate remedies"... Additionally, shares of Cisco (CSCO) dropped 4.1% after The Information reported that Amazon Web Services (AMZN) is considering selling its own networking switches for business customers. Arista Networks (ANET) and Juniper (JNPR) also fell 4.3% and 2.3%, respectively, after the news. MAJOR MOVERS: Among the noteworthy gainers was Biocept (BIOC), which surged 9.8% after it announced a provider agreement with Alliance Global FZ. Also higher was Achillion (ACHN), which gained 7.2% after it said it began dosing in its Phase 1 trial of ACH-5548. Among the notable losers was Gogo (GOGO), which fell 16.2% following the company's announcement of a strategic review. Also lower was Ingredion (INGR), which dropped 10.2% after it provided lower than expected Q2 guidance and cut its outlook for fiscal 2018. INDEXES: The Dow rose 94.52, or 0.38%, to 25,019.41, the Nasdaq gained 2.06, or 0.02%, to 7,825.98, and the S&P 500 advanced 3.02, or 0.11%, to 2,801.31.

CSCO

Cisco

$41.77

-1.81 (-4.15%)

AMZN

Amazon.com

$1,813.00

15.99 (0.89%)

JPM

JPMorgan

$106.33

-0.47 (-0.44%)

WFC

Wells Fargo

$55.35

-0.67 (-1.20%)

C

Citi

$67.00

-1.54 (-2.25%)

PNC

PNC Financial

$138.29

0.29 (0.21%)

T

AT&T

$31.66

-0.56 (-1.74%)

JNJ

Johnson & Johnson

$125.94

-1.83 (-1.43%)

ANET

Arista Networks

$266.14

-12.335 (-4.43%)

JNPR

Juniper

$27.86

-0.645 (-2.26%)

BIOC

Biocept

$7.10

0.61 (9.40%)

ACHN

Achillion

$3.13

0.2 (6.83%)

GOGO

Gogo

$4.03

-0.81 (-16.74%)

INGR

Ingredion

$99.43

-11.3 (-10.21%)

  • 13

    Jul

  • 13

    Jul

  • 13

    Jul

  • 13

    Jul

  • 13

    Jul

  • 17

    Jul

  • 18

    Jul

  • 24

    Jul

  • 26

    Jul

  • 26

    Jul

  • 02

    Aug

  • 02

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 16

    Aug

  • 21

    Aug

  • 29

    Aug

  • 04

    Sep

  • 12

    Oct

  • 12

    Oct

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 15

    Oct

  • 15

    Oct

CSCO Cisco
$41.77

-1.81 (-4.15%)

07/05/18
ARGS
07/05/18
NO CHANGE
Target $90
ARGS
Buy
NetApp price target raised to $90 from $76 at Argus
Argus analyst Jim Kelleher raised his price target on NetApp (NTAP) to $90 and kept his Buy rating, citing the company's new offerings along with its partner Cisco (CSCO) in their FlexPod data management solutions business. The analyst notes that the first of these solutions designed to simplify IT infrastructure and data management for healthcare customers and organizations has already been launched, with more verticals expected to be addressed by additional solutions later this year. While "vanishing into Cisco's vast P&L", Kelleher tells investors that FlexPod is a material part of NetApp's business, adding that its market share may grow as rival Dell EMC is focused to bring a part of the company public.
07/09/18
PIPR
07/09/18
NO CHANGE
Target $50
PIPR
Overweight
Piper checks imply Cisco losing security share to Palo Alto
Piper Jaffray analyst James Fish says his firm's recent channel survey work across networking and security were weaker than he's have seen in past calendar quarters for Cisco Systems (CSCO). Cisco in previous quarters had positive 40% net-scores in Networking compared to a negative 2% this quarter, suggesting a more in-line quarter, Fish tells investors in a research note. Further, Cisco's Security survey results were "especially weak," implying Palo Alto Networks (PANW) is taking market share, the analyst adds. Fish "slightly reduced" his estimates for Cisco but says the stock remains his top networking pick. He keeps an Overweight rating on the name with a $50 price target.
07/13/18
RBCM
07/13/18
NO CHANGE
RBCM
RBC says Amazon entry would be 'notable negative' for Cisco, networking peers
After The Information reported that Amazon's (AMZN) AWS unit is now targeting the data center switching market, RBC Capital analyst Mitch Steves said that, if true, this would be a notable negative for those in the networking equipment space, including Cisco (CSCO), Arista Networks (ANET) and Juniper Networks (JNPR). While others have created their own white-box hardware, none have created a commercial product so far and AWS would be the first major commercial provider of white-box switches, said Steves, who also said "it is important to note" that current sales and revenue trends will likely be safe since the report said a launch could potentially occur in 18 months. He also thinks Cisco and Arista in particular have "solid" software products that would help them compete against a new entrant such as AWS.
07/09/18
07/09/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GAMESTOP STARTED WITH A BUY: Jefferies analyst Stephanie Wissink started GameStop (GME) with a Buy rating and $18 price target. Her contrarian view on the stock is that under potential new leadership with a well defined vision and execution plan, the stock's valuation, which she feels is "overlooked and overly discounted," could improve. GameStop is higher by 2.5% in midday trading. PIPER SEES CISCO LOSING SECURITY SHARE TO PALO ALTO: Piper Jaffray analyst James Fish says his firm's recent channel survey work across networking and security were weaker than he's seen in past calendar quarters for Cisco Systems (CSCO). Cisco's Security survey results were "especially weak," implying Palo Alto Networks (PANW) is taking market share, the analyst said, although the former remains his top networking pick. He kept an Overweight rating on Cisco shares, which were down almost 1% in midday trading. JEFFERIES DOWNGRADES P&G: Jefferies analyst Kevin Grundy downgraded Procter & Gamble (PG) to Hold from Buy and lowered his price target for the shares to $79 from $83. Slowing market growth, volatility in emerging markets, U.S. retail difficulties, the stronger U.S. dollar and "pricing challenges" should drive estimates lower, Grundy told investors in a research note titled "Tide Unlikely to Turn: Downgrade to Hold as Bull Thesis Wanes." Grundy said he preferred shares of Church & Dwight (CHD) and Energizer (ENR) for exposure to the Home and Personal Care space. TRADE DESK STARTED WITH A SELL: Pivotal Research analyst Brian Wieser initiated Trade Desk (TTD) with a Sell rating and $58 price target, stating that he believes the company can grow rapidly this year but should then see its growth decelerate. He believes its growth will plateau at a size smaller than Criteo's (CRTO), on which Wieser also initiated coverage this morning with a Buy rating. WELLS FARGO DOWNGRADES TWO THEME PARKS: Wells Fargo analyst Timothy Conder downgraded both SeaWorld (SEAS) and Six Flags (SIX) to Market Perform from Outperform, citing valuation, negative seasonal trading patterns, and weather impact, despite ongoing favorable consumer fundamentals and the key Q3 just starting. SeaWorld is trading down 1.3%, while Six Flags is down 1.7% at midday.
AMZN Amazon.com
$1,813.00

15.99 (0.89%)

07/13/18
JEFF
07/13/18
NO CHANGE
Target $240
JEFF
Buy
Facebook price target raised to $240 from $215 at Jefferies
Jefferies analyst Brent Thill raised his price target for Facebook (FB) shares to $240 from $215 ahead of the Q2 reporting season for the Internet space. The social media giant closed yesterday up 2% to $206.98. Amazon.com (AMZN), Facebook and Google (GOOGL) are the analyst's top large-cap picks into the earnings season. Expedia (EXPE) is Thill's top value play while IAC (IAC) and GoDaddy (GDDY) are his favorite names among smaller caps. Facebook continues to be the best return on investment for advertisers as Instagram shows continued strength and more ad opportunities are being added, Thill tells investors in a research note on the Internet space. He sees earnings per share of $10-plus "on the horizon." A 25-30 times multiple off that yields a stock price of $250-$300 for Facebook, the analyst points out. Thill keeps a Buy rating on the name.
07/13/18
JPMS
07/13/18
NO CHANGE
JPMS
Amazon reported datacenter switching plans negative for Nokia, says JPMorgan
JPMorgan analyst Sandeep Deshpande said Amazon's (AMZN) reported potential foray into datacenter switching is a negative for Nokia's (NOK) efforts in the enterprise market. While it does not surprise him that AWS uses white-box switches in its datacenters, a move toward launching commercial products would be and he believes such a launch would have a negative read-across to Nokia, which recently launched its FP4-powered platform for core routing. If AWS enters, Nokia's product will need to be substantially differentiated for customers to choose it, added Deshpande.
07/13/18
LEHM
07/13/18
NO CHANGE
Target $1850
LEHM
Overweight
Amazon.com price target raised to $1,850 from $1,700 at Barclays
Barclays analyst Ross Sandler backed an Overweight rating on Amazon and raised his price target to $1,850, telling investors in a research note that the company is likely to report broadly in line revenue and another solid OI quarter in Q2. Sandler, who believes the company may guide conservatively for Q3 on FX and seasonally low OI, says he would add to positions into the print as Amazon has traded up four out of the past seven July earnings, and says Amazon is one of his favorite long-term ideas in consumer internet.
JPM JPMorgan
$106.33

-0.47 (-0.44%)

06/21/18
BERN
06/21/18
NO CHANGE
BERN
Amazon/JPMorgan/Berkshire venture still negative for drug supply chain, says Bernstein
Bernstein analyst Lance Wilkes notes that Amazon (AMZN), Berkshire Hathaway (BRK.A; BRK.B) and JPMorgan (JPM) announced the appointment of Atul Gawande as the CEO of their new healthcare joint venture, effective July 9th. The analyst sees this appointment as indicating an emphasis on enablement of change in the system, along with thought and policy leadership, and believes the appointment of an operating oriented President or COO could refine the outlook for scope. Wilkes continues to see this venture as negative for drug supply chain and self-insured employer oriented MCOs.
06/29/18
DBAB
06/29/18
NO CHANGE
DBAB
Deutsche declares Wells Fargo, SunTrust, Huntington the CCAR winners
Deutsche Bank analyst Matt O'Connor views Wells Fargo (WFC), SunTrust (STI) and Huntington Bancshares (HBAN) as the winners of the Federal Reserve's Comprehensive Capital Analysis and Review. The banks separately disclosed planned dividend increases and buybacks for the next four quarters, O'Connor tells investors in a research note. He points out that while JPMorgan (JPM), KeyCorp (KEY) and M&T Bank (MTB) "all used the mulligan," he does not view this as negative.
07/09/18
GSCO
07/09/18
NO CHANGE
GSCO
Bank of America, Morgan Stanley top ideas into Q2 earnings season, says Goldman Sachs
Goldman Sachs analyst Richard Ramsden expects Bank of America (BAC) and Morgan Stanley (MS) to beat consensus estimates in Q2. The analyst argues that both appear best positioned, while he sees risk for U.S. Bancorp (USB) and JPMorgan (JPM). Ramsden highlights Bank of America given the material valuation dislocation that looks to support the stock over time. Additionally, the analyst expects an expense and NII beat for Morgan Stanley.
06/08/18
BERN
06/08/18
NO CHANGE
BERN
Bernstein offers list of possible CEOs for Amazon-Berkshire-JPMorgan venture
After Berkshire' (BRK.A) Warren Buffett and JPMorgan's (JPM) Jamie Dimon announced on CNBC that they have selected a CEO for their healthcare joint venture with Amazon (AMZN) and added that they would announce the name in about two weeks, Bernstein analyst Lance Wilkes noted that Geisinger CEO David Feinberg denied accepting the position and said he is committed to Geisinger. The ultimate choice of the CEO will inform on the intended scope of the NewCo and how the companies will prioritize strategic direction and needed capabilities, said Wilkes, who offered a list of potential CEO candidates that includes Gary Loveman, Rick Jelinek, Matt Manders, Patrick Conway, Amir Rubin, Owen Tripp, Chris Grant, Marc Harrison, Andy Slavitt, Todd Park and Peter Orszag.
WFC Wells Fargo
$55.35

-0.67 (-1.20%)

07/02/18
07/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. RPM (RPM) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas saying he believes investors are now more willing to pay a higher multiple for RPM EBITDA because of new possibilities of cost reduction, changes in capital structure, or overall changes to the company given the involvement of activist Elliott Management. 2. Capital One (COF) upgraded to Outperform from Neutral at Credit Suisse with analyst Moshe Orenbuch citing improving credit quality, ahead of the industry. 3. Wells Fargo (WFC) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Betsy Graseck stating that the bank's passing the 2018 CCAR stress test removes an overhang and indicates to her that the Fed is receptive of the changes Wells is making. 4. ZTE Corp. (ZTCOY) upgraded to Buy from Underperform at Jefferies with analyst Edison Lee saying Li Zixue becoming Chairman of the Board is an important step toward meeting the conditions of the company's settlement with the U.S. 5. Curtiss-Wright (CW) upgraded to Outperform from Market Perform at William Blair with analyst Nicholas Heymann saying the valuation is "compelling" following the recent correction in the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/02/18
07/02/18
UPGRADE
Target $62

Equal Weight
Wells Fargo upgraded to Equal Weight after CCAR test pass at Morgan Stanley
As previously reported, Morgan Stanley analyst Betsy Graseck upgraded Wells Fargo to Equal Weight from Underweight, stating that the bank's passing the 2018 CCAR stress test removes an overhang and indicates to her that the Fed is receptive of the changes Wells is making. Not only did Wells pass, the Fed approved buybacks that were almost twice her estimates, Graseck tells investors. Higher buybacks took her EPS estimate up 4% and Graseck raised her price target on Wells Fargo shares to $62 from $57.
06/29/18
06/29/18
NO CHANGE

Goldman says Wells Fargo, Huntington, Regions among biggest winners of CCAR
Goldman Sachs analyst Richard Ramsden said the Fed's CCAR results came in largely better than expected, calling Wells Fargo (WFC), Huntington Bancshares (HBAN), Regions Financial (RF), SunTrust (STI) and Fifth Third (FITB) the biggest relative winners in his view. He believes the market will be focused on banks' 25% dividend growth announcements and believes the CCAR results can be a catalyst for a relief rally.
07/02/18
MSCO
07/02/18
UPGRADE
MSCO
Equal Weight
Wells Fargo upgraded to Equal Weight from Underweight at Morgan Stanley
C Citi
$67.00

-1.54 (-2.25%)

06/20/18
DBAB
06/20/18
UPGRADE
Target $76
DBAB
Buy
Citi upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Matt O'Connor upgraded Citi (C) to Buy and raised his price target for the shares to $76 from $74. The analyst also calls Goldman Sachs (GS) and Wells Fargo (WFC) his top picks ahead of the Q2 reporting season.
05/17/18
DAIW
05/17/18
DOWNGRADE
DAIW
Buy
Citi downgraded to Buy from Strong Buy at Daiwa
06/20/18
06/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Citi (C) upgraded to Buy from Hold at Deutsche Bank. 2. BT Group (BT) upgraded to Buy from Hold at Jefferies with analyst Jeremy Dellis saying reducing the dividend to increase investment in fiber-to-the-premises networks to satisfy demands by British telecommunications regulator Ofcom could make BT a "geat deal more investable." 3. Duke Energy (DUK) upgraded to Buy from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing recent share underperformance and resolved regulatory overhangs. 4. Glatfelter (GLT) upgraded to Buy from Neutral at DA Davidson with analyst Steven Chercover saying he is "incrementally positive" on the stock based on his view of the announced acquisition of GP's European airlaid nonwoven business, which adds 35K tonnes per year in capacity to the company's existing 129K tpy. 5. Intelsat (I) upgraded to Outperform from Sector Perform at RBC Capital with analyst Wilton Fry citing his expected FCC release of the Notice of Proposed Rulemaking this week that will lead to adoption of the company's C-band proposal, "conservatively" estimating that this could add over $19 in earnings per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/18
OPCO
06/29/18
NO CHANGE
Target $88
OPCO
Outperform
Oppenheimer says 'particularly pleased' with Citi's $17.6B share buyback
Following the release of CCAR results for 2018, Oppenheimer analysts Chris Kotowski and Ben Chittenden told investors in a research note that they are "particularly pleased" with Citi's (C) $17.6B share buyback, up 13% from last year and above their $16.5B estimate, while the dividend increase to 45c was also 5c better than expected. The analysts noted that both Goldman (GS) and Morgan Stanley (MS) got "conditional passes" on their capital plans, as both banks "ran a bit afoul" of the supplementary leverage ratio limitation.
PNC PNC Financial
$138.29

0.29 (0.21%)

01/16/18
RBCM
01/16/18
NO CHANGE
Target $170
RBCM
Top Pick
PNC Financial price target raised to $170 from $145 at RBC Capital
RBC Capital analyst Gerard Cassidy raised his price target to $170 after the bank's above-consensus Q4 earnings driven by "stronger noninterest income and a lower loan loss provision". The analyst also noted a 0.9% increase in PNC's average loan and the expected positive impact from lower U.S. corporate tax rates. Cassidy keeps his Top Pick rating on PNC, forecasting continued strong results in 2018-2019, assuming 2-3 interest rate increases in each year.
04/16/18
BARD
04/16/18
NO CHANGE
Target $153
BARD
Outperform
PNC Financial weakness overdone, says Baird
Baird analyst David George said PNC Financial posted a clean quarter and he would be a buyer of the shares on the post-earnings weakness. The analyst noted fees were down seasonally, but the bank posted good year-over-year growth. George maintained his Outperform rating and $153 price target on PNC Financial shares.
06/14/18
RBCM
06/14/18
NO CHANGE
Target $170
RBCM
Top Pick
PNC Financial EPS view cut at RBC Capital on reduced mortgage banking outlook
RBC Capital analyst Gerard Cassidy lowered his PNC Financial FY18 EPS view to $10.51 from $10.60 and FY19 view to $11.32 from $11.46 after the recent commentary by the management that its Q2 mortgage banking revenues are tracking to be 12% lower than in Q1. The analyst keeps his Top Pick rating and $170 price target however, saying the bank is well positioned for higher interest rates that would expand its net interest income and also has a high 42% of the total component for its non-interest income. Cassidy adds that the regulatory environment benefits could also exceed his expectations.
05/30/18
BARD
05/30/18
NO CHANGE
Target $153
BARD
Outperform
PNC Financial added as Fresh Pick at Baird
Baird analyst David George said the weakness in PNC Financial is a buying opportunity and said it screens as one of the better values among regional banks. The analyst likes the bank's competitive positioning, solid intermediate-term outlook, and its current valuation. George reiterated his Outperform rating and $153 price target on PNC Financial shares.
T AT&T
$31.66

-0.56 (-1.74%)

07/13/18
07/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AT&T (T) downgraded to Market Perform from Outperform at Raymond James with analyst Frank Louthan saying he views the Department of Justice appeal of the Time Warner case as a negative and said it is a "frustrating delay." Louthan expects the suit to be a "significant overhang" for an extended period of time, which will limit share appreciation, but remains confident AT&T will prevail. 2. Incyte (INCY) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Matthew Harrison saying he believes key catalysts are unlikely until 2019 and he expects the stock to trade with the market in the meantime. 3. WisdomTree (WETF) was downgraded to Market Perform from Outperform at Keefe Bruyette and to Neutral from Buy at Citi. 4. Cedar Fair (FUN) downgraded to Neutral from Outperform at Macquarie. 5. Ingredion (INGR) downgraded to Sell from Neutral at Citi with analyst David Driscoll saying he expects the stock's valuation multiples to compress as investors sort through the number of issues that have come to light. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/18
MSCO
07/13/18
NO CHANGE
Target $37
MSCO
Overweight
Market likely to place low odds on AT&T deal reversal, says Morgan Stanley
After the DOJ decided to appeal District Court Judge Leon's order approving AT&T's merger with Time Warner, Morgan Stanley analyst Simon Flannery said he believes the market is likely to heavily rely on Judge Leon's "strongly worded decision" and assign a fairly low probability on a possible reversal of the deal. Even if AT&T were forced to divest assets, it would be into a fairly healthy market, added Flannery, who keeps an Overweight rating and $37 price target on the stock.
07/13/18
07/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. VF CORP DOUBLE UPGRADE: BofA Merrill Lynch analyst Robert Ohmes upgraded VF Corp (VFC) to Buy from Underperform and raised his price objective to $96 from $65 ahead of the company's earnings report on July 20, telling investors in a research note that he believes Vans will be a "go-to-brand" for the back-to-school selling season. He said his channel checks indicate accelerating momentum in Vans, especially classic styles, and that the $50-$60 price point is attractive given consumers' shift to value. RAYMOND JAMES DOWNGRADES AT&T: Raymond James downgraded AT&T (T) to Market Perform from Outperform. Analyst Frank Louthan said he views the Department of Justice appeal of the Time Warner case as a negative and said it is a "frustrating delay." Louthan expects the suit to be a "significant overhang" for an extended period of time, which will limit share appreciation, but remains confident AT&T will prevail. AT&T is lower by 2% in late morning trading. STIFEL STARTS GALMED WITH A BUY: Stifel analyst Adam Walsh initiated Galmed (GLMD) with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play" after Aramchol recently proved itself in a Phase 2 trial as a clearly active and "very safe" compound for treating NASH. Galmed is trading higher by over 17% in late morning trading. MORGAN STANLEY HIKES WWE TARGET TO $100: Morgan Stanley analyst Benjamin Swinburne said that WWE (WWE), by securing rights fees in its new five-year agreements with NBC (CMCSA, CMCSK) and Fox (FOX, FOXA) that are 3.6 times higher than its prior five-year broadcast agreement with NBC, has gained a "massive increase" in earnings power and "extremely high" visibility into the associated revenue. Given the recently announced deals, he raised his price target on WWE shares to $100 from $58 and kept an Overweight rating on the stock. WILLIAM BLAIR CALLS KEMPER PULLBACK 'BUYING OPPORTUNITY': William Blair analyst Adam Klauber said he views shares of Kemper (KMPR) as "even more attractive" after the recent pullback, which he attributes to selling pressures from Infinity Property shareholders receiving Kemper stock. Klauber said Kemper "continues to be our top conviction idea," and kept an Outpeform rating on the name. Kemper is higher by 4.8% in late morning trading.
07/13/18
JEFF
07/13/18
NO CHANGE
Target $35
JEFF
Hold
DOJ faces 'uphill battle' in AT&T appeal, says Jefferies
While the Department of Justice's appeal of the AT&T-Time Warner case creates some uncertainty, the agency "faces an uphill battle," Jefferies analyst John Janedis tells investors in a research note. The analyst notes that Judge Leon was very clear in his ruling that he believed the government did not meet its burden of proof in the case, and discouraged the DOJ from asking for a stay. Janedis believes it could take a year or more before a final decision is made. He keeps a Hold rating on AT&T with a $35 price target.
JNJ Johnson & Johnson
$125.94

-1.83 (-1.43%)

07/12/18
GSCO
07/12/18
UPGRADE
GSCO
Neutral
Johnson & Johnson upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $134. The shares closed yesterday down $1.11 to $126.24. The stock is down 10% year-to-date and 15% from its recent all-time high of $148, Rubin tells investors in a research note. She notes J&J is trading in line with the large cap Pharmaceuticals group at 15 times 2019 estimates. The company's non-operational earnings revisions are now better understood by investors at current share levels, Rubin contends. The analyst this morning also downgraded Perrigo (PRGO) to Sell from Neutral.
07/13/18
FBCO
07/13/18
NO CHANGE
Target $151
FBCO
Outperform
J&J verdict likely to increase attention on lawsuits, says Credit Suisse
After a Missouri jury on Thursday ordered Johnson & Johnson to pay $4.69B to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer, Credit Suisse analyst Vamil Divan said the large number of ongoing litigations are gaining the attention of investors and is not expected to slow. Given the number of cases related to both talc and mesh and the size of the potential verdicts, Divan says it is "challenging" to put reasonable ranges on what J&J's ultimate liability may end up being, though he notes that J&J has been able to overturn many of the cases and has appealed all of the unfavorable verdicts. Divan maintains an Outperform rating and $151 price target.
07/12/18
07/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Sell at Goldman Sachs with analyst Jami Rubin saying the stock is down 10% year-to-date and 15% from its recent all-time high of $148. 2. Hallmark Financial (HALL) upgraded to Outperform from Market Perform at Raymond James. 3. Transocean (RIG), Ensco (ESV), and Rowan Companies (RDC) were upgraded to Buy from Hold at Tudor Pickering. 4. Precision Drilling (PDS) and Nabors Industries (NBR) were upgraded to Overweight from Equal Weight at Morgan Stanley. 5. CA Technologies (CA) upgraded to Market Perform from Underperform at Wells Fargo and Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
ANET Arista Networks
$266.14

-12.335 (-4.43%)

06/28/18
FBCO
06/28/18
NO CHANGE
Target $303
FBCO
Outperform
Arista continues to take share in data center switching, says Credit Suisse
Credit Suisse analyst Sami Badri notes Arista Networks (ANET) continues to take over the data center switching market. According to I.H.S. Markit, Arista grew its revenue market share in Q1 to 14.8%, taking share away from Cisco (CSCO) and Huawei. The analyst recommends Arista for its strong market position, as it grew its market share 210bps, and highlights its strength in the DC market as the company was able to maintain its product revenues on an absolute basis, despite Q1 being a seasonally weak quarter across the industry. Badri reiterates an Outperform rating and $303 price target on Arista shares.
07/09/18
PIPR
07/09/18
UPGRADE
Target $315
PIPR
Overweight
Arista Networks upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst James Fish upgraded Arista Networks to Overweight and raised his price target for the shares to $315 from $268. The analyst says his firm's Q2 networking channel survey suggest suggests another quarter of upside for Arista.
07/09/18
PIPR
07/09/18
UPGRADE
Target $315
PIPR
Overweight
Piper upgrades Arista to Overweight on 'strong' demand trends
Piper Jaffray analyst James Fish upgraded Arista Networks to Overweight from Neutral and raised his price target for the shares to $315 from $268. The analyst's Q2 channel survey suggests Arista will report revenue of at least $519M, above the Street's estimate of $510M. Investor expectations are not as high as past quarters, presenting a potential near-term catalyst when the company reports on August 2, Fish tells investors in a research note. He sees "strong" demand trends for the company and lowered investor sentiment.
JNPR Juniper
$27.86

-0.645 (-2.26%)

06/15/18
06/15/18
DOWNGRADE
Target $24

Sell
Juniper downgraded to Sell on key account weakening at Rosenblatt
As previously reported, Rosenblatt analyst Ryan Koontz downgraded Juniper (JNPR) to Sell from Neutral, stating that he believes the company is starting to see weakness in several key accounts, including AT&T (T), Comcast (CMCSA), and Alphabet (GOOGL). Those three customers collectively represent about 15% of sales, Koontz estimates. He cut his second half revenue and EPS estimates for Juniper to below consensus and lowered his price target on the shares to $24 from $28.
07/11/18
07/11/18
UPGRADE

Mixed
Juniper upgraded to Mixed following checks at OTR Global
As previously reported, OTR Global upgraded Juniper to Mixed from Negative. The firm's checks indicate router and switch sales improved at Juniper partners during Q2, but weakness in security and aggressive competitive continued to limit gains.
07/11/18
OTRG
07/11/18
UPGRADE
OTRG
Mixed
Juniper upgraded to Mixed from Negative at OTR Global
BIOC Biocept
$7.10

0.61 (9.40%)

05/23/18
WEST
05/23/18
DOWNGRADE
WEST
Neutral
Biocept downgraded to Neutral from Outperform at WestPark Capital
WestPark Capital analyst Lauren Chung downgraded Biocept to Neutral citing "limited funds to the balance sheet" following the company's Q1 results. The analyst wants to see an inflection in sales growth, or a strategic partnership, before getting more constructive on the shares.
04/04/18
WEST
04/04/18
NO CHANGE
Target $1
WEST
Outperform
Biocept price target lowered to $1 from $3 at WestPark Capital
WestPark Capital analyst Lauren Chung lowered her price target for Biocept to $1 following the company's Q4 results but maintains an Outperform rating on the name. While sales growth is slower than expected, Biocept continues to make "meaningful progress as an emerging pure play liquid biopsy diagnostics company," Chung tells investors in a post-earnings research note. Further, she views the Thermo Fisher collaboration as promising.
10/04/17
WEST
10/04/17
NO CHANGE
WEST
Biocept marketing agreement a positive, says WestPark Capital
WestPark Capital analyst Lauren Chung said Biocept's new promotion and marketing agreement with Miraca Life Sciences to market Biocept's tests and services in the U.S. will let Biocept to more aggressively boost sales without incurring material cost to the company, and could expand Biocept's reach for tests country wide. Chung rates Biocept a Buy with a $3 price target.
ACHN Achillion
$3.13

0.2 (6.83%)

02/08/18
RILY
02/08/18
INITIATION
Target $3.5
RILY
Neutral
Achillion initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Achillion Pharmaceuticals with a Neutral rating and $3.50 price target.
12/15/17
LEER
12/15/17
NO CHANGE
Target $5
LEER
Outperform
Achillion CMO departure not a sign of problems with pipeline, says Leerink
Leerink analyst Joseph Schwartz spoke with Achillion after news that CMO David Apelian delivered his resignation and the analyst believes his departure is not indicative of any problems with the company's pipeline programs. Schwartz, who continues to see current levels as an attractive entry point to buy shares ahead of more de-risking data next year in the C3G market, keeps an Outperform rating on Achillion.
12/11/17
LEER
12/11/17
NO CHANGE
Target $5
LEER
Outperform
Achillion '4471 on its way toward meaningful remissions, says Leerink
After speaking with MEDACorp nephrologists and conducting an analysis of recent data on the first two patients with C3 glomerulopathy treated with Achillion's ACH-4471, Leerink analyst Joseph Schwartz has an "enhanced appreciation" of the early signal of decreased proteinuria and market opportunity for it in C3G. The analyst believes '4471 is converging on modified partial remissions, which the FDA has stated may be used as a primary endpoint in other orphan kidney diseases. Schwartz is looking forward to data updates in 2018 on higher doses, longer duration of therapy, and more patients. He reiterates an Outperform rating and $5 price target on the shares.
05/21/18
LEHM
05/21/18
UPGRADE
Target $5
LEHM
Equal Weight
Achillion upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Geoffrey Meacham upgraded Achillion Pharmaceuticals to Equal Weight with an unchanged price target of $5. The analyst sees minimal downside risk from current valuation levels.
GOGO Gogo
$4.03

-0.81 (-16.74%)

04/11/18
WBLR
04/11/18
NO CHANGE
WBLR
Google interest ups chances of in-flight Wi-Fi acquisition, says William Blair
"We have seen this movie before" is what William Blair analyst Louie DiPalma says after Bloomberg reported yesterday that Google (GOOG, GOOGL) is in advanced talks to acquire Nokia's in-flight connectivity hardware business. Google joins a long list of technology, telecom, and media providers that have exhibited a strategic interest in in-flight Wi-Fi, "although all have thus far stayed on the perimeter," DiPalma tells investors in a research note. The analyst notes that incumbents Gogo (GOGO), Panasonic (PCRFY), ViaSat (VSAT), Global Eagle Entertainment (ENT), and Inmarsat (IMASY) have invested billions toward satellite capacity and infrastructure. The industry is all about scale and potential new entrants would not have any, DiPalma contends. He believes it would take any new entrant many years to build a network from scratch, obtain regulatory approvals, and procure line-fit partnerships. The analyst thinks Google's interest in in-flight connectivity increases the probability that a tech or telecom company would buy an incumbent in the space. DiPalma has Outperform ratings on ViaSat and Gogo and a Market Perform rating on Global Eagle.
05/30/18
MSCO
05/30/18
NO CHANGE
Target $3
MSCO
Underweight
Gogo price target lowered to $3 from $7 at Morgan Stanley
Morgan Stanley analyst Simon Flannery said Gogo's recent weak results raise questions about its underlying business, financial model and ability to generate positive free cash flow. Given his expectations for significantly lower commercial aviation North America revenue and profitability, Flannery cut his 2018 adjusted EBITDA estimate for Gogo by about 55% and his 2019/2020 estimates by about 15%. He lowered his price target on Gogo shares to $3 from $7 and maintains an Underweight rating on the stock.
05/21/18
UBSW
05/21/18
DOWNGRADE
Target $7
UBSW
Neutral
Gogo downgraded to Neutral from Buy at UBS
UBS downgraded Gogo to Neutral from Buy and lowered its price target to $7 from $14.
05/18/18
NORL
05/18/18
NO CHANGE
Target $1.5
NORL
Underperform
Gogo price target lowered to $1.50 from $3.50 at Northland
Norhtland analyst Paul Penney believes Gogo's issues remain "far reaching and deep," and as a result, cut estimates to take in account lower business and profitability levels. Penney said Gogo's excessive capex spending levels are not sustainable and expects continued equity erosion, leading the analyst to cut his price target to $1.50 from $3.50 and reiterate an Underperform rating.
INGR Ingredion
$99.43

-11.3 (-10.21%)

07/13/18
SBSH
07/13/18
DOWNGRADE
SBSH
Sell
Ingredion downgraded to Sell from Neutral at Citi
07/13/18
07/13/18
DOWNGRADE
Target $95

Sell
Ingredion downgraded to Sell after guidance cut at Citi
As previously reported, Citi analyst David Driscoll downgraded Ingredion to Sell from Neutral after the company lowered its Q2 and 2018 EPS forecast, stating that he expects the stock's valuation multiples to compress as investors sort through the number of issues that have come to light. He set a $95 price target on Ingredion shares.
07/13/18
07/13/18
NO CHANGE
Target $145

Buy
Ingredion long-term thesis remains intact, says Jefferies
Jefferies analyst Akshay Jagdale says the long-term thesis on Ingredion remains intact despite the company's "disappointing" Q2 preannouncement. HFCS is a fairly small portion of Ingredion's overall portfolio and been in secular decline for some time, Jagdale tells investors in a research note. The analyst's long-term thesis is predicated more on Specialty business growth, which he says remains on track. Further, he believes the newly announced cost savings program should accelerate margin expansion. Jagdale reiterates a Buy rating on Ingredion with a $145 price target.

TODAY'S FREE FLY STORIES

HTHT

China Lodging

$41.02

0.76 (1.89%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Conference/Events
China Lodging management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 22

    Aug

IRWD

Ironwood

$20.03

-0.035 (-0.17%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Initiation
Ironwood initiated  »

Ironwood initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLIR

Flir Systems

$53.96

-0.55 (-1.01%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Conference/Events
Flir Systems management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

ARCT

Arcturus Therapeutics

$8.40

-0.09 (-1.06%)

07:09
07/23/18
07/23
07:09
07/23/18
07:09
Hot Stocks
Arcturus achieves program milestones, refines agreement with CF Foundation »

Arcturus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$46.43

(0.00%)

07:08
07/23/18
07/23
07:08
07/23/18
07:08
Conference/Events
Reata Pharmaceuticals to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LAD

Lithia Motors

$95.34

-0.85 (-0.88%)

07:07
07/23/18
07/23
07:07
07/23/18
07:07
Hot Stocks
Lithia Motors announces Erik Lewis as CHRO »

Lithia Motors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

KALA

Kala Pharmaceuticals

$12.28

-0.19 (-1.52%)

07:07
07/23/18
07/23
07:07
07/23/18
07:07
Initiation
Kala Pharmaceuticals initiated  »

Kala Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Aug

JMEI

Jumei

$2.07

-0.05 (-2.36%)

07:06
07/23/18
07/23
07:06
07/23/18
07:06
Hot Stocks
Jumei announces $27.6M in share repurchase since April »

Jumei announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$46.57

0.47 (1.02%)

07:05
07/23/18
07/23
07:05
07/23/18
07:05
Hot Stocks
Acceleron reports preliminary results from Part 1 of ACE-083 Phase 2 trial »

Acceleron Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNVC

NanoViricides

$0.41

-0.002 (-0.49%)

, OHRP

Ohr Pharmaceutical

$0.20

-0.0019 (-0.94%)

07:05
07/23/18
07/23
07:05
07/23/18
07:05
Hot Stocks
NanoViricides names Dr. Irach Taraporewala as new CEO »

NanoViricides (NNVC) is…

NNVC

NanoViricides

$0.41

-0.002 (-0.49%)

OHRP

Ohr Pharmaceutical

$0.20

-0.0019 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
07/23/18
07/23
07:05
07/23/18
07:05
General news
Oil Action: Front-month WTI prices are up 1.2% »

Oil Action: Front-month…

WVE

Wave Life Sciences

$39.05

1.15 (3.03%)

07:04
07/23/18
07/23
07:04
07/23/18
07:04
Initiation
Wave Life Sciences initiated  »

Wave Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$17.63

-0.09 (-0.51%)

07:04
07/23/18
07/23
07:04
07/23/18
07:04
Hot Stocks
McDermott awarded EPC contract in Saudi Arabia »

McDermott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

AGTC

Applied Genetic

$4.05

-0.15 (-3.57%)

, BIIB

Biogen

$358.72

0.55 (0.15%)

07:04
07/23/18
07/23
07:04
07/23/18
07:04
Hot Stocks
Applied Genetic treats first patient of second cohort in clinical XLRP study »

Applied Genetic (AGTC)…

AGTC

Applied Genetic

$4.05

-0.15 (-3.57%)

BIIB

Biogen

$358.72

0.55 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

OPB

Opus Bank

$29.65

-0.2 (-0.67%)

07:04
07/23/18
07/23
07:04
07/23/18
07:04
Earnings
Opus Bank reports Q2 EPS 40c, consensus 39c »

Net income of $15.5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 07

    Nov

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

07:03
07/23/18
07/23
07:03
07/23/18
07:03
Recommendations
Amazon.com analyst commentary  »

Wedbush expects Amazon to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

FSIC

FS Investment

$7.90

(0.00%)

, CCT

Corporate Capital Trust

$16.76

-0.11 (-0.65%)

07:03
07/23/18
07/23
07:03
07/23/18
07:03
Hot Stocks
FS/KKR announces agreement to merge FS Investment, Corporate Capital Trust »

FS/KKR Advisor, LLC, a…

FSIC

FS Investment

$7.90

(0.00%)

CCT

Corporate Capital Trust

$16.76

-0.11 (-0.65%)

KKR

KKR

$27.26

0.21 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

GLOW

Glowpoint

$0.18

0.004 (2.29%)

07:02
07/23/18
07/23
07:02
07/23/18
07:02
Hot Stocks
Glowpoint announces authorization of stock buyback program »

Glowpoint announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

, APO

Apollo Global

$35.39

-0.22 (-0.62%)

07:02
07/23/18
07/23
07:02
07/23/18
07:02
Hot Stocks
Breaking Hot Stocks news story on LifePoint, Apollo Global »

LifePoint shareholders to…

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

APO

Apollo Global

$35.39

-0.22 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 02

    Aug

  • 22

    Aug

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

, APO

Apollo Global

$35.39

-0.22 (-0.62%)

07:02
07/23/18
07/23
07:02
07/23/18
07:02
Hot Stocks
LifePoint to merge with Apollo's RCCH HealthCare Partners »

LifePoint Health (LPNT)…

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

APO

Apollo Global

$35.39

-0.22 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 02

    Aug

  • 22

    Aug

SGMO

Sangamo

$15.10

0.025 (0.17%)

07:01
07/23/18
07/23
07:01
07/23/18
07:01
Hot Stocks
Sangamo announces first treatment of patient in Phase 1/2 trial of SB-318 »

Sangamo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EPZM

Epizyme

$13.35

-0.25 (-1.84%)

07:01
07/23/18
07/23
07:01
07/23/18
07:01
Hot Stocks
Epizyme appoints Dr. Shefali Agarwal as Chief Medical Officer »

Epizyme announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

COST

Costco

$218.70

1.14 (0.52%)

07:00
07/23/18
07/23
07:00
07/23/18
07:00
Recommendations
Costco analyst commentary  »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOO

Teekay Offshore Partners

$2.50

-0.05 (-1.96%)

07:00
07/23/18
07/23
07:00
07/23/18
07:00
Hot Stocks
Teekay Offshore GP appoints Jan Steinsland as CFO »

Teekay Offshore GP, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBM

Cambrex

$56.05

0.35 (0.63%)

06:58
07/23/18
07/23
06:58
07/23/18
06:58
Conference/Events
Cambrex to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.